围绕晚期前列腺癌联合雄激素阻断疗法的二十年争议。 - Suppr

Suppr

超能文献

Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.

作者信息

Moul Judd W

出版信息

Cancer. 2009 Aug 1;115(15):3376-8. doi: 10.1002/cncr.24393.

DOI:10.1002/cncr.24393

PMID:19484788

Abstract

摘要

相似文献

Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.

Cancer. 2009 Aug 1;115(15):3376-8. doi: 10.1002/cncr.24393.

Maximal androgen blockade for advanced prostate cancer.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):331-40. doi: 10.1016/j.beem.2008.01.004.

The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.

Jpn J Clin Oncol. 2012 Jun;42(6):534-40. doi: 10.1093/jjco/hys037. Epub 2012 Mar 20.

[Hormonal treatment of cancer of the prostate: review and present status].

Dtsch Med Wochenschr. 2007 Jan 26;132(4):161-6. doi: 10.1055/s-2007-959305.

Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer.

BJU Int. 2011 Jun;107(12):1918-22. doi: 10.1111/j.1464-410X.2010.09804.x. Epub 2010 Nov 2.

Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.

Jpn J Clin Oncol. 2008 Sep;38(9):617-22. doi: 10.1093/jjco/hyn071. Epub 2008 Aug 12.

[Total androgen blockade].

Nihon Rinsho. 2002 Dec;60 Suppl 11:193-8.

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.

Cancer. 2009 Aug 1;115(15):3437-45. doi: 10.1002/cncr.24395.

Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.

BJU Int. 2007 Jan;99 Suppl 1:10-2; discussion 17-8. doi: 10.1111/j.1464-410X.2007.06593.x.

[Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].

Urologiia. 2001 Nov-Dec(6):20-1.

引用本文的文献

Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy.

World J Surg Oncol. 2021 Jan 4;19(1):5. doi: 10.1186/s12957-020-02111-3.

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.

Jpn J Clin Oncol. 2018 Nov 1;48(11):1012-1021. doi: 10.1093/jjco/hyy129.

Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Urol Ann. 2016 Apr-Jun;8(2):123-30. doi: 10.4103/0974-7796.176872.

Hormone naïve prostate cancer: predicting and maximizing response intervals.

Asian J Androl. 2015 Nov-Dec;17(6):929-35; discussion 933. doi: 10.4103/1008-682X.152821.

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies.

Oncol Rev. 2013 Sep 25;7(1):e6. doi: 10.4081/oncol.2013.e6. eCollection 2013 Apr 22.

Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Urol Ann. 2014 Oct;6(4):278-85. doi: 10.4103/0974-7796.140959.

SEOM clinical guidelines for treatment of prostate cancer.

Clin Transl Oncol. 2012 Jul;14(7):520-7. doi: 10.1007/s12094-012-0835-x.

Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade.

Korean J Urol. 2011 Jul;52(7):461-5. doi: 10.4111/kju.2011.52.7.461. Epub 2011 Jul 24.

Saudi Oncology Society clinical management guidelines for prostate cancer.

Urol Ann. 2011 Mar;3 Suppl(Suppl):S10-6. doi: 10.4103/0974-7796.78550.

Proven efficacy of combined androgen depletion therapy.

Curr Urol Rep. 2010 Jul;11(4):221-3. doi: 10.1007/s11934-010-0117-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验